Parkinson’s disease (PD) is a heterogeneous neurodegenerative disease involving multiple etiologies and pathogenesis, in which neuroinflammation is a common factor. Both preclinical experiments and clinical studies provide evidence for the involvement of neuroinflammation in the pathophysiology of PD, although there are a number of key issues related to neuroinflammatory processes in PD that remain to be addressed. In this review, we highlight the relationship between the common pathological mechanisms of PD and neuroinflammation, including aggregation of α-synuclein, genetic factors, mitochondrial dysfunction, and gut microbiome dysbiosis. We also describe the two positive feedback loops initiated in PD after the immune system is activated, and their role in the pathogenesis of PD. In addition, the interconnections and differences between the central and peripheral immune systems are discussed. Finally, we review the latest progress in immunotherapy research for PD patients, and propose future directions for clinical research.
AcuñaLHamadatSCorbalánNSGonzález-LizárragaFDos-Santos-PereiraMRoccaJ others. 2019. Rifampicin and its derivative rifampicin quinone reduce microglial inflammatory responses and neurodegeneration induced in vitro by α-synuclein fibrillary aggregates. Cells8(8):776.
2.
AgarwalSYadavAChaturvediRK. 2017. Peroxisome proliferator-activated receptors (PPARs) as therapeutic target in neurodegenerative disorders. Biochem Biophys Res Commun483(4):1166–77.
3.
AhmedITamouzaRDelordMKrishnamoorthyRTzourioCMulotC others. 2012. Association between Parkinson’s disease and the HLA-DRB1 locus. Mov Disord27(9):1104–10.
4.
AliseychikMPAndreevaTVRogaevEI. 2018. Immunogenetic factors of neurodegenerative diseases: the role of HLA class II. Biochemistry (Mosc)83(9):1104–16.
5.
AtashrazmFHammondDPereraGDobson-StoneCMuellerNPickfordR others. 2018. Reduced glucocerebrosidase activity in monocytes from patients with Parkinson’s disease. Sci Rep8(1):15446.
6.
BabaYKuroiwaAUittiRJWszolekZKYamadaT. 2005. Alterations of T-lymphocyte populations in Parkinson disease. Parkinsonism Relat Disord11(8):493–8.
7.
BecherBSpathSGovermanJ. 2017. Cytokine networks in neuroinflammation. Nat Rev Immunol17(1):49–59.
8.
BeilinaARudenkoINKaganovichACivieroLChauHKaliaSK others. 2014. Unbiased screen for interactors of leucine-rich repeat kinase 2 supports a common pathway for sporadic and familial Parkinson disease. Proc Natl Acad Sci U S A111(7):2626–31.
9.
BenderAKrishnanKJMorrisCMTaylorGAReeveAKPerryRH others. 2006. High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nat Genet38(5):515–7.
10.
BennerEJMosleyRLDestacheCJLewisTBJackson-LewisVGorantlaS others. 2004. Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson’s disease. Proc Natl Acad Sci U S A101(25):9435–40.
11.
BéraudDTwomeyMBloomBMitterederATonVNeitzkeK others. 2011. α-Synuclein alters toll-like receptor expression. Front Neurosci5:80.
12.
BhattacharyaPBudnickISinghMThiruppathiMAlharshawiKElshabrawyH others. 2015. Dual role of GM-CSF as a pro-inflammatory and a regulatory cytokine: implications for immune therapy. J Interferon Cytokine Res35(8):585–99.
13.
BrakedalBFlønesIReiterSFTorkildsenØDölleCAssmusJ others. 2017. Glitazone use associated with reduced risk of Parkinson’s disease. Mov Disord32(11):1594–9.
14.
BrauerRBhaskaranKChaturvediNDexterDTSmeethLDouglasI. 2015. Glitazone treatment and incidence of Parkinson’s disease among people with diabetes: a retrospective cohort study. PLoS Med12(7):e1001854.
15.
BrochardVCombadièreBPrigentALaouarYPerrinABeray-BerthatV others. 2009. Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest119(1):182–92.
16.
BrysMFanningLHungSEllenbogenAPennerNYangM others. 2019. Randomized phase I clinical trial of anti-α-synuclein antibody BIIB054. Mov Disord34(8):1154–63.
17.
BuryAGPyleAElsonJLGreavesLMorrisCMHudsonG others. 2017. Mitochondrial DNA changes in pedunculopontine cholinergic neurons in Parkinson disease. Ann Neurol82(6):1016–21.
18.
BylickyMAMuellerGPDayRM. 2018. Mechanisms of endogenous neuroprotective effects of astrocytes in brain injury. Oxid Med Cell Longev2018:6501031.
ChangDNallsMAHallgrímsdóttirIBHunkapillerJvan der BrugMCaiF others. 2017. A meta-analysis of genome-wide association studies identifies 17 new Parkinson’s disease risk loci. Nat Genet49(10):1511–6.
21.
ChenJSuPLuoWChenJ. 2018. Role of LRRK2 in manganese-induced neuroinflammation and microglial autophagy. Biochem Biophys Res Commun498(1):171–7.
22.
ChiuCCLuCSWengYHChenYLHuangYZChenRS others. 2019. PARK14 (D331Y) PLA2G6 causes early-onset degeneration of substantia nigra dopaminergic neurons by inducing mitochondrial dysfunction, ER stress, mitophagy impairment and transcriptional dysregulation in a knockin mouse model. Mol Neurobiol56(6):3835–53.
23.
ChoiNMMajumderPBossJM. 2011. Regulation of major histocompatibility complex class II genes. Curr Opin Immunol23(1):81–7.
24.
ChungYCShinWHBaekJYChoEJBaikHHKimSR others. 2016. CB2 receptor activation prevents glial-derived neurotoxic mediator production, BBB leakage and peripheral immune cell infiltration and rescues dopamine neurons in the MPTP model of Parkinson’s disease. Exp Mol Med48(1):e205.
25.
CirsteaMSYuACGolzESundvickKKligerDRadisavljevicN others. 2020. Microbiota composition and metabolism are associated with gut function in Parkinson’s disease. Mov Disord35(7):1208–17.
26.
ClarkIEDodsonMWJiangCCaoJHHuhJRSeolJH others. 2006. Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature441(7097):1162–6.
27.
ConnollyJGBykovKGagneJJ. 2015. Thiazolidinediones and Parkinson disease: a cohort study. Am J Epidemiol182(11):936–44.
28.
CooksonMR. 2016. Cellular functions of LRRK2 implicate vesicular trafficking pathways in Parkinson’s disease. Biochem Soc Trans44(6):1603–10.
29.
CoseSBrammerCKhannaKMMasopustDLefrançoisL. 2006. Evidence that a significant number of naive T cells enter non-lymphoid organs as part of a normal migratory pathway. Eur J Immunol36(6):1423–33.
30.
CouchYAlvarez-ErvitiLSibsonNRWoodMJAnthonyDC. 2011. The acute inflammatory response to intranigral α-synuclein differs significantly from intranigral lipopolysaccharide and is exacerbated by peripheral inflammation. J Neuroinflammation8:166.
31.
DanieleSGBéraudDDavenportCChengKYinHMaguire-ZeissKA. 2015. Activation of MyD88-dependent TLR1/2 signaling by misfolded α-synuclein, a protein linked to neurodegenerative disorders. Sci Signal8(376):ra45.
32.
DasuMRRiosvelascoACJialalI. 2009. Candesartan inhibits toll-like receptor expression and activity both in vitro and in vivo. Atherosclerosis202(1):76–83.
33.
de LeonMJLiYOkamuraNTsuiWHSaint-LouisLAGlodzikL others. 2017. Cerebrospinal fluid clearance in Alzheimer disease measured with dynamic PET. J Nucl Med58(9):1471–6.
34.
DehmerTHenekaMTSastreMDichgansJSchulzJB. 2004. Protection by pioglitazone in the MPTP model of Parkinson’s disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation. J Neurochem88(2):494–501.
35.
DelgadoMChornyAGonzalez-ReyEGaneaD. 2005. Vasoactive intestinal peptide generates CD4+CD25+ regulatory T cells in vivo. J Leukoc Biol78(6):1327–38.
36.
DengHWangPJankovicJ. 2018. The genetics of Parkinson disease. Ageing Res Rev42:72–85.
37.
DepboyluCStrickerSGhobrilJPOertelWHPrillerJHöglingerGU. 2012. Brain-resident microglia predominate over infiltrating myeloid cells in activation, phagocytosis and interaction with T-lymphocytes in the MPTP mouse model of Parkinson disease. Exp Neurol238(2):183–91.
38.
DeviLRaghavendranVPrabhuBMAvadhaniNGAnandatheerthavaradaHK. 2008. Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. J Biol Chem283(14):9089–100.
39.
DuLZhangYChenYZhuJYangYZhangHL. 2017. Role of microglia in neurological disorders and their potentials as a therapeutic target. Mol Neurobiol54(10):7567–84.
40.
DuffyMFCollierTJPattersonJRKempCJLukKCTanseyMG others. 2018. Correction to: Lewy body-like alpha-synuclein inclusions trigger reactive microgliosis prior to nigral degeneration. J Neuroinflammation15(1):169.
41.
ErnyDHrabědeAngelisALJaitinDWieghoferPStaszewskiODavidE others. 2015. Host microbiota constantly control maturation and function of microglia in the CNS. Nat Neurosci18(7):965–77.
42.
FaucheuxBABonnetAMAgidYHirschEC. 1999. Blood vessels change in the mesencephalon of patients with Parkinson’s disease. Lancet353(9157):981–2.
43.
FellnerLIrschickRSchandaKReindlMKlimaschewskiLPoeweW others. 2013. Toll-like receptor 4 is required for α-synuclein dependent activation of microglia and astroglia. Glia61(3):349–60.
44.
FiszerUMixEFredriksonSKostulasVLinkH. 1994. Parkinson’s disease and immunological abnormalities: increase of HLA-DR expression on monocytes in cerebrospinal fluid and of CD45RO+ T cells in peripheral blood. Acta Neurol Scand90(3):160–6.
45.
FlorenzanoFBentivoglioM. 2000. Degranulation, density, and distribution of mast cells in the rat thalamus: a light and electron microscopic study in basal conditions and after intracerebroventricular administration of nerve growth factor. J Comp Neurol424(4):651–69.
46.
FooJNChungSJTanLCLianyHRyuHSHongM others. 2016. Linking a genome-wide association study signal to a LRRK2 coding variant in Parkinson’s disease. Mov Disord31(4):484–7.
47.
FooJNTanLCIrwanIDAuWLLowHQPrakashKM others. 2017. Genome-wide association study of Parkinson’s disease in East Asians. Hum Mol Genet26(1):226–32.
48.
GamesDValeraESpencerBRockensteinEManteMAdameA others. 2014. Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson’s disease-like models. J Neurosci34(28):9441–54.
49.
GaoXChenHSchwarzschildMAAscherioA. 2011. Use of ibuprofen and risk of Parkinson disease. Neurology76(10):863–9.
50.
GendelmanHEZhangYSantamariaPOlsonKESchuttCRBhattiD others. 2017. Evaluation of the safety and immunomodulatory effects of sargramostim in a randomized, double-blind phase 1 clinical Parkinson’s disease trial. NPJ Parkinsons Dis3:10.
51.
GerhardAPaveseNHottonGTurkheimerFEsMHammersA others. 2006. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson’s disease. Neurobiol Dis21(2):404–12.
52.
GoldzweigOHashkesPJ. 2011. Abatacept in the treatment of polyarticular JIA: development, clinical utility, and place in therapy. Drug Des Devel Ther5:61–70.
53.
GordonRAlbornozEAChristieDCLangleyMRKumarVMantovaniS others. 2018. Inflammasome inhibition prevents α-synuclein pathology and dopaminergic neurodegeneration in mice. Sci Transl Med10(465):eaah4066.
54.
GrazioliSPuginJ. 2018. Mitochondrial damage-associated molecular patterns: from inflammatory signaling to human diseases. Front Immunol9:832.
55.
GreenfieldEANguyenKAKuchrooVK. 1998. CD28/B7 costimulation: a review. Crit Rev Immunol18(5):389–418.
56.
GrozdanovVBoussetLHoffmeisterMBliederhaeuserCMeierCMadionaK others. 2019. Increased immune activation by pathologic α-synuclein in Parkinson’s disease. Ann Neurol86(4):593–606.
HammerJValsasniniPTolbaKBolinDHigelinJTakacsB others. 1993. Promiscuous and allele-specific anchors in HLA-DR-binding peptides. Cell74(1):197–203.
59.
HamzaTHZabetianCPTenesaALaederachAMontimurroJYearoutD others. 2010. Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson’s disease. Nat Genet42(9):781–5.
60.
HarmsASCaoSRowseALThomeADLiXMangieriLR others. 2013. MHCII is required for α-synuclein-induced activation of microglia, CD4 T cell proliferation, and dopaminergic neurodegeneration. J Neurosci33(23):9592–600.
61.
HarmsASThomeADYanZSchonhoffAMWilliamsGPLiX others. 2018. Peripheral monocyte entry is required for alpha-Synuclein induced inflammation and neurodegeneration in a model of Parkinson disease. Exp Neurol300:179–87.
62.
HayesGMWoodroofeMNCuznerML. 1987. Microglia are the major cell type expressing MHC class II in human white matter. J Neurol Sci80(1):25–37.
63.
HenryAGAghamohammadzadehSSamarooHChenYMouKNeedleE others. 2015. Pathogenic LRRK2 mutations, through increased kinase activity, produce enlarged lysosomes with reduced degradative capacity and increase ATP13A2 expression. Hum Mol Genet24(21):6013–28.
64.
HirschECHunotS. 2009. Neuroinflammation in Parkinson’s disease: a target for neuroprotection?Lancet Neurol8(4):382–97.
65.
HirschECStandaertDG. 2020. Ten unsolved questions about neuroinflammation in Parkinson’s disease. Mov Disord. EpubMay1. doi:10.1002/mds.28075
66.
HonggeLKexinGXiaojieMNianXJinshaH. 2015. The role of LRRK2 in the regulation of monocyte adhesion to endothelial cells. J Mol Neurosci55(1):233–9.
67.
HuXIvashkivLB. 2009. Cross-regulation of signaling pathways by interferon-gamma: implications for immune responses and autoimmune diseases. Immunity31(4):539–50.
68.
HughesCDChoiMLRytenMHopkinsLDrewsABotíaJA others. 2019. Picomolar concentrations of oligomeric alpha-synuclein sensitizes TLR4 to play an initiating role in Parkinson’s disease pathogenesis. Acta Neuropathol137(1):103–20.
69.
IbaMKimCSallinMKwonSVermaAOverkC others. 2020. Neuroinflammation is associated with infiltration of T cells in Lewy body disease and α-synuclein transgenic models. J Neuroinflammation17(1):214.
70.
IliffJJWangMLiaoYPloggBAPengWGundersenGA others. 2012. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid β. Sci Transl Med4(147):147ra111.
71.
IrrcherIAleyasinHSeifertELHewittSJChhabraSPhillipsM others. 2010. Loss of the Parkinson’s disease-linked gene DJ-1 perturbs mitochondrial dynamics. Hum Mol Genet19(19):3734–46.
72.
JanelidzeSLindqvistDFrancardoVHallSZetterbergHBlennowK others. 2015. Increased CSF biomarkers of angiogenesis in Parkinson disease. Neurology85(21):1834–42.
73.
JankovicJ. 2019. Pathogenesis-targeted therapeutic strategies in Parkinson’s disease. Mov Disord34(1):41–4.
74.
JankovicJGoodmanISafirsteinBMarmonTKSchenkDBKollerM others. 2018. Safety and tolerability of multiple ascending doses of PRX002/RG7935, an anti-α-synuclein monoclonal antibody, in patients with Parkinson disease: a randomized clinical trial. JAMA Neurol75(10):1206–14.
75.
JavedHAzimullahSHaqueMEOjhaSK. 2016. Cannabinoid type 2 (CB2) receptors activation protects against oxidative stress and neuroinflammation associated dopaminergic neurodegeneration in rotenone model of Parkinson’s disease. Front Neurosci10:321.
76.
Jimenez-FerrerIBäckströmFDueñas-ReyAJewettMBoza-SerranoALukKC others. 2021. The MHC class II transactivator modulates seeded alpha-synuclein pathology and dopaminergic neurodegeneration in an in vivo rat model of Parkinson’s disease. Brain Behav Immun91:369–82.
KampFExnerNLutzAKWenderNHegermannJBrunnerB others. 2010. Inhibition of mitochondrial fusion by α-synuclein is rescued by PINK1, Parkin and DJ-1. EMBO J29(20):3571–89.
80.
KempurajDAhmedMESelvakumarGPThangavelRRaikwarSPZaheerSA others. 2020. Mast cell activation, neuroinflammation, and tight junction protein derangement in acute traumatic brain injury. Mediators Inflamm2020:4243953.
81.
KempurajDSelvakumarGPZaheerSThangavelRAhmedMERaikwarS others. 2018. Cross-talk between glia, neurons and mast cells in neuroinflammation associated with Parkinson’s disease. J Neuroimmune Pharmacol13(1):100–12.
KimBWKoppulaSKumarHParkJYKimIWMoreSV others. 2015. α-Asarone attenuates microglia-mediated neuroinflammation by inhibiting NF kappa B activation and mitigates MPTP-induced behavioral deficits in a mouse model of Parkinson’s disease. Neuropharmacology97:46–57.
84.
KimCHoDHSukJEYouSMichaelSKangJ others. 2013. Neuron-released oligomeric α-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia. Nat Commun4:1562.
85.
KimCSpencerBRockensteinEYamakadoHManteMAdameA others. 2018. Immunotherapy targeting toll-like receptor 2 alleviates neurodegeneration in models of synucleinopathy by modulating α-synuclein transmission and neuroinflammation. Mol Neurodegener13(1):43.
86.
KimJSRyuSYYunIKimWJLeeKSParkJW others. 2006. 1alpha,25-Dihydroxyvitamin D(3) protects dopaminergic neurons in rodent models of Parkinson’s disease through inhibition of microglial activation. J Clin Neurol2(4):252–7.
87.
KimSKwonSHKamTIPanickerNKaruppagounderSSLeeS others. 2019. Transneuronal propagation of pathologic α-synuclein from the gut to the brain models Parkinson’s disease. Neuron103(4):627–641.e7.
88.
KingEThomasA. 2017. Systemic inflammation in Lewy body diseases: a systematic review. Alzheimer Dis Assoc Disord31(4):346–56.
89.
KirkADHarlanDMArmstrongNNDavisTADongYGrayGS others. 1997. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci U S A94(16):8789–94.
KorhonenRMoilanenE. 2009. Abatacept, a novel CD80/86-CD28 T cell co-stimulation modulator, in the treatment of rheumatoid arthritis. Basic Clin Pharmacol Toxicol104(4):276–84.
92.
KortekaasRLeendersKLvan OostromJCVaalburgWBartJWillemsenAT others. 2005. Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Ann Neurol57(2):176–9.
93.
KosloskiLMKosmacekEAOlsonKEMosleyRLGendelmanHE. 2013. GM-CSF induces neuroprotective and anti-inflammatory responses in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine intoxicated mice. J Neuroimmunol 265(1–2):1–10.
94.
KouliACamachoMAllinsonKWilliams-GrayCH. 2020. Neuroinflammation and protein pathology in Parkinson’s disease dementia. Acta Neuropathol Commun8(1):211.
95.
KuhnCWeinerHL. 2016. Therapeutic anti-CD3 monoclonal antibodies: from bench to bedside. Immunotherapy8(8):889–906.
96.
LarsenCPPearsonTCAdamsABTsoPShirasugiNStrobertE others. 2005. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant5(3):443–53.
97.
LeeHJSukJEBaeEJLeeSJ. 2008. Clearance and deposition of extracellular alpha-synuclein aggregates in microglia. Biochem Biophys Res Commun372(3):423–8.
98.
LickerVTurckNKövariEBurkhardtKCôteMSurini-DemiriM others. 2014. Proteomic analysis of human substantia nigra identifies novel candidates involved in Parkinson’s disease pathogenesis. Proteomics14(6):784–94.
99.
LiddelowSAGuttenplanKAClarkeLEBennettFCBohlenCJSchirmerL others. 2017. Neurotoxic reactive astrocytes are induced by activated microglia. Nature541(7638):481–7.
100.
LinCHChenCCChiangHLLiouJMChangCMLuTP others. 2019. Altered gut microbiota and inflammatory cytokine responses in patients with Parkinson’s disease. J Neuroinflammation16(1):129.
101.
Lindestam ArlehamnCSDhanwaniRPhamJKuanRFrazierARezende DutraJ others. 2020. α-Synuclein-specific T cell reactivity is associated with preclinical and early Parkinson’s disease. Nat Commun11(1):1875.
102.
LinsleyPSBradyWUrnesMGrosmaireLSDamleNKLedbetterJA. 1991. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med174(3):561–9.
103.
LinsleyPSGreeneJLTanPBradshawJLedbetterJAAnasettiC others. 1992. Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes. J Exp Med176(6):1595–604.
104.
LiuZHuangYCaoBBQiuYHPengYP. 2017a. Th17 cells induce dopaminergic neuronal death via LFA-1/ICAM-1 interaction in a mouse model of Parkinson’s disease. Mol Neurobiol54(10):7762–76.
105.
LiuYXieXXiaLPLvHLouFRenY others. 2017b. Peripheral immune tolerance alleviates the intracranial lipopolysaccharide injection-induced neuroinflammation and protects the dopaminergic neurons from neuroinflammation-related neurotoxicity. J Neuroinflammation14(1):223.
106.
LouveauASmirnovIKeyesTJEcclesJDRouhaniSJPeskeJD others. 2015. Structural and functional features of central nervous system lymphatic vessels. Nature523(7560):337–41.
MandlerMValeraERockensteinEManteMWeningerHPatrickC others. 2015. Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy. Mol Neurodegener10:10.
109.
MandlerMValeraERockensteinEWeningerHPatrickCAdameA others. 2014. Next-generation active immunization approach for synucleinopathies: implications for Parkinson’s disease clinical trials. Acta Neuropathol127(6):861–79.
McGeerPLItagakiSBoyesBEMcGeerEG. 1988. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson’s and Alzheimer’s disease brains. Neurology38(8):1285–91.
112.
MishraASinghSTiwariVChaturvediSWahajuddinMShuklaS. 2019. Dopamine receptor activation mitigates mitochondrial dysfunction and oxidative stress to enhance dopaminergic neurogenesis in 6-OHDA lesioned rats: a role of Wnt signalling. Neurochem Int129:104463.
113.
MorschMRadfordRLeeADonEKBadrockAPHallTE others. 2015. In vivo characterization of microglial engulfment of dying neurons in the zebrafish spinal cord. Front Cell Neurosci9:321.
114.
MortiboysHJohansenKKAaslyJOBandmannO. 2010. Mitochondrial impairment in patients with Parkinson disease with the G2019S mutation in LRRK2. Neurology75(22):2017–20.
115.
MullinSSchapiraAH. 2015. Pathogenic mechanisms of neurodegeneration in Parkinson disease. Neurol Clin33(1):1–17.
116.
NagatsuTMogiMIchinoseHTogariA. 2000. Changes in cytokines and neurotrophins in Parkinson’s disease. J Neural Transm Suppl (60):277–90.
117.
NallsMABlauwendraatCVallergaCLHeilbronKBandres-CigaSChangD others. 2019. Identification of novel risk loci, causal insights, and heritable risk for Parkinson’s disease: a meta-analysis of genome-wide association studies. Lancet Neurol18(12):1091–102.
118.
NallsMAPlagnolVHernandezDGSharmaMSheerinUMSaadM others. 2011. Imputation of sequence variants for identification of genetic risks for Parkinson’s disease: a meta-analysis of genome-wide association studies. Lancet377(9766):641–9.
119.
NavarreteFGarcía-GutiérrezMSAracil-FernándezALanciegoJLManzanaresJ. 2018. Cannabinoid CB1 and CB2 receptors, and monoacylglycerol lipase gene expression alterations in the basal ganglia of patients with Parkinson’s disease. Neurotherapeutics15(2):459–69.
120.
NeniskyteUVilaltaABrownGC. 2014. Tumour necrosis factor alpha-induced neuronal loss is mediated by microglial phagocytosis. FEBS Lett588(17):2952–6.
121.
NissenSKFerreiraSANielsenMCSchulteCShrivastavaKHennigD others. 2020. Soluble CD163 changes indicate monocyte association with cognitive deficits in Parkinson’s disease. Mov Disord. Epub Dec 17. doi:10.1002/mds.28424
122.
NissenSKShrivastavaKSchulteCOtzenDEGoldeckDBergD others. 2019. Alterations in blood monocyte functions in Parkinson’s disease. Mov Disord34(11):1711–21.
123.
NoelkerCMorelLOsterlohAAlvarez-FischerDLescotTBreloerM others. 2014. Heat shock protein 60: an endogenous inducer of dopaminergic cell death in Parkinson disease. J Neuroinflammation11:86.
124.
ObesoJAStamelouMGoetzCGPoeweWLangAEWeintraubD others. 2017. Past, present, and future of Parkinson’s disease: a special essay on the 200th anniversary of the shaking palsy. Mov Disord32(9):1264–310.
125.
OlsonKEBadeANSchuttCRDongJShandlerSJBoskaMD others. 2016. Manganese-enhanced magnetic resonance imaging for detection of vasoactive intestinal peptide receptor 2 agonist therapy in a model of Parkinson’s disease. Neurotherapeutics13(3):635–46.
126.
OrihuelaRMcPhersonCAHarryGJ. 2016. Microglial M1/M2 polarization and metabolic states. Br J Pharmacol173(4):649–65.
127.
PanickerNSarkarSHarischandraDSNealMKamTIJinH others. 2019. Fyn kinase regulates misfolded α-synuclein uptake and NLRP3 inflammasome activation in microglia. J Exp Med216(6):1411–30.
128.
ParasharAUdayabanuM. 2017. Gut microbiota: implications in Parkinson’s disease. Parkinsonism Relat Disord38:1–7.
129.
PenarandaCTangQBluestoneJA. 2011. Anti-CD3 therapy promotes tolerance by selectively depleting pathogenic cells while preserving regulatory T cells. J Immunol187(4):2015–22.
130.
PeterIDubinskyMBressmanSParkALuCChenN others. 2018. Anti-tumor necrosis factor therapy and incidence of Parkinson disease among patients with inflammatory bowel disease. JAMA Neurol75(8):939–46.
131.
PrasadKVCaiYCRaabMDuckworthBCantleyLShoelsonSE others. 1994. T-cell antigen CD28 interacts with the lipid kinase phosphatidylinositol 3-kinase by a cytoplasmic Tyr(P)-Met-Xaa-Met motif. Proc Natl Acad Sci U S A91(7):2834–8.
132.
QinHBuckleyJALiXLiuYFoxTH3rdMearesGP others. 2016. Inhibition of the JAK/STAT pathway protects against α-synuclein-induced neuroinflammation and dopaminergic neurodegeneration. J Neurosci36(18):5144–59.
133.
RacetteBAGrossAVouriSMCamacho-SotoAWillisAWSearles NielsenS. 2018. Immunosuppressants and risk of Parkinson disease. Ann Clin Transl Neurol5(7):870–5.
134.
RansohoffRM. 2016. A polarizing question: do M1 and M2 microglia exist?Nat Neurosci19(8):987–91.
135.
ReynoldsADStoneDKMosleyRLGendelmanHE. 2009. Nitrated α-synuclein-induced alterations in microglial immunity are regulated by CD4+ T cell subsets. J Immunol182(7):4137–49.
136.
RingstadGVatneholSASEidePK. 2017. Glymphatic MRI in idiopathic normal pressure hydrocephalus. Brain140(10):2691–705.
137.
RochfortKDCollinsLEMurphyRPCumminsPM. 2014. Downregulation of blood-brain barrier phenotype by proinflammatory cytokines involves NADPH oxidase-dependent ROS generation: consequences for interendothelial adherens and tight junctions. PLoS One9(7):e101815.
138.
RostamiJFotakiGSiroisJMzezewaRBergströmJEssandM others. 2020. Astrocytes have the capacity to act as antigen-presenting cells in the Parkinson’s disease brain. J Neuroinflammation17(1):119.
139.
RussoIKaganovichADingJLandeckNMamaisAVaranitaT others. 2019. Transcriptome analysis of LRRK2 knock-out microglia cells reveals alterations of inflammatory- and oxidative stress-related pathways upon treatment with α-synuclein fibrils. Neurobiol Dis129:67–78.
140.
SampsonTRDebeliusJWThronTJanssenSShastriGGIlhanZE others. 2016. Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson’s disease. Cell167(6):1469–1480.e12.
141.
SarkarSDammerEBMalovicEOlsenALRazaSAGaoT others. 2020. Molecular signatures of neuroinflammation induced by α-synuclein aggregates in microglial cells. Front Immunol11:33.
142.
SaundersJAEstesKAKosloskiLMAllenHEDempseyKMTorres-RussottoDR others. 2012. CD4+ regulatory and effector/memory T cell subsets profile motor dysfunction in Parkinson’s disease. J Neuroimmune Pharmacol7(4):927–38.
143.
SavittDJankovicJ. 2019. Targeting α-synuclein in Parkinson’s disease: progress towards the development of disease-modifying therapeutics. Drugs79(8):797–810.
144.
SchreckRRieberPBaeuerlePA. 1991. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kappa B transcription factor and HIV-1. EMBO J10(8):2247–58.
145.
SchröderJBPawlowskiMMeyerZuHörsteGGrossCCWiendlHMeuthSG others. 2018. Immune cell activation in the cerebrospinal fluid of patients with Parkinson’s disease. Front Neurol9:1081.
146.
SchuttCRGendelmanHEMosleyRL. 2018. Tolerogenic bone marrow-derived dendritic cells induce neuroprotective regulatory T cells in a model of Parkinson’s disease. Mol Neurodegener13(1):26.
147.
SchwiertzASpiegelJDillmannUGrundmannDBürmannJFaßbenderK others. 2018. Fecal markers of intestinal inflammation and intestinal permeability are elevated in Parkinson’s disease. Parkinsonism Relat Disord50:104–7.
148.
ShaoWZhangSZTangMZhangXHZhouZYinYQ others. 2013. Suppression of neuroinflammation by astrocytic dopamine D2 receptors via αB-crystallin. Nature494(7435):90–4.
149.
SliterDAMartinezJHaoLChenXSunNFischerTD others. 2018. Parkin and PINK1 mitigate STING-induced inflammation. Nature561(7722):258–62.
150.
SommerAMarxreiterFKrachFFadlerTGroschJMaroniM others. 2018. Th17 lymphocytes induce neuronal cell death in a human iPSC-based model of Parkinson’s disease. Cell Stem Cell23(1):123–131.e6.
151.
StegerMTonelliFItoGDaviesPTrostMVetterM others. 2016. Phosphoproteomics reveals that Parkinson’s disease kinase LRRK2 regulates a subset of Rab GTPases. Elife5.
152.
SuXMaguire-ZeissKAGiulianoRPriftiLVenkateshKFederoffHJ. 2008. Synuclein activates microglia in a model of Parkinson’s disease. Neurobiol Aging29(11):1690–701.
153.
SulzerDAlcalayRNGarrettiFCoteLKanterEAgin-LiebesJ others. 2017. T cells from patients with Parkinson’s disease recognize α-synuclein peptides. Nature546(7660):656–61.
154.
SwansonCRJoersVBondarenkoVBrunnerKSimmonsHAZieglerTE others. 2011. The PPAR-γ agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys. J Neuroinflammation8:91.
TeradaTYokokuraMYoshikawaEFutatsubashiMKonoSKonishiT others. 2016. Extrastriatal spreading of microglial activation in Parkinson’s disease: a positron emission tomography study. Ann Nucl Med30(8):579–87.
157.
TheodoreSCaoSMcLeanPJStandaertDG. 2008. Targeted overexpression of human alpha-synuclein triggers microglial activation and an adaptive immune response in a mouse model of Parkinson disease. J Neuropathol Exp Neurol67(12):1149–58.
158.
TurkheimerFERizzoGBloomfieldPSHowesOZanotti-FregonaraPBertoldoA others. 2015. The methodology of TSPO imaging with positron emission tomography. Biochem Soc Trans43(4):586–92.
159.
VincentiFBlanchoGDurrbachAFriendPGrinyoJHalloranPF others. 2010. Five-year safety and efficacy of belatacept in renal transplantation. J Am Soc Nephrol21(9):1587–96.
160.
Volpicelli-DaleyLBrundinP. 2018. Prion-like propagation of pathology in Parkinson disease. Handb Clin Neurol153:321–35.
161.
WadaKAraiHTakanashiMFukaeJOizumiHYasudaT others. 2006. Expression levels of vascular endothelial growth factor and its receptors in Parkinson’s disease. Neuroreport17(7):705–9.
162.
WaismanAJohannL. 2018. Antigen-presenting cell diversity for T cell reactivation in central nervous system autoimmunity. J Mol Med (Berl)96(12):1279–92.
163.
WangSJingHYangHLiuZGuoHChaiL others. 2015. Tanshinone I selectively suppresses pro-inflammatory genes expression in activated microglia and prevents nigrostriatal dopaminergic neurodegeneration in a mouse model of Parkinson’s disease. J Ethnopharmacol164:247–55.
164.
WangYShaHZhouLChenYZhouQDongH others. 2020. The mast cell is an early activator of lipopolysaccharide-induced neuroinflammation and blood-brain barrier dysfunction in the hippocampus. Mediators Inflamm2020:8098439.
165.
WeihofenALiuYArndtJWHuyCQuanCSmithBA others. 2019. Development of an aggregate-selective, human-derived α-synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson’s disease models. Neurobiol Dis124:276–88.
166.
WijeyekoonRSKronenberg-VersteegDScottKMHayatSJonesJLClatworthyMR others. 2018. Monocyte function in Parkinson’s disease and the impact of autologous serum on phagocytosis. Front Neurol9:870.
167.
WijeyekoonRSMooreSFFarrellKBreenDPBarkerRAWilliams-GrayCH. 2020. Cerebrospinal fluid cytokines and neurodegeneration-associated proteins in Parkinson’s disease. Mov Disord35(6):1062–66.
168.
WilliamsGPSchonhoffAMJurkuvenaiteAThomeADStandaertDGHarmsAS. 2018. Targeting of the class II transactivator attenuates inflammation and neurodegeneration in an alpha-synuclein model of Parkinson’s disease. J Neuroinflammation15(1):244.
169.
WissemannWTHill-BurnsEMZabetianCPFactorSAPatsopoulosNHoglundB others. 2013. Association of Parkinson disease with structural and regulatory variants in the HLA region. Am J Hum Genet93(5):984–93.
170.
WitoelarAJansenIEWangYDesikanRSGibbsJRBlauwendraatC others. 2017. Genome-wide pleiotropy between Parkinson disease and autoimmune diseases. JAMA Neurol74(7):780–92.
171.
YamasakiRLuHButovskyOOhnoNRietschAMCialicR others. 2014. Differential roles of microglia and monocytes in the inflamed central nervous system. J Exp Med211(8):1533–49.
172.
YunSPKamTIPanickerNKimSOhYParkJS others. 2018. Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson’s disease. Nat Med24(7):931–8.
173.
ZhangQItagakiKHauserCJ. 2010. Mitochondrial DNA is released by shock and activates neutrophils via p38 map kinase. Shock34(1):55–9.
174.
ZhangWWangTPeiZMillerDSWuXBlockML others. 2005. Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson’s disease. FASEB J19(6):533–42.
175.
ZhouPHombergJRFangQWangJLiWMengX others. 2019. Histamine-4 receptor antagonist JNJ7777120 inhibits pro-inflammatory microglia and prevents the progression of Parkinson-like pathology and behaviour in a rat model. Brain Behav Immun76:61–73.
176.
ZhouRYazdiASMenuPTschoppJ. 2011. A role for mitochondria in NLRP3 inflammasome activation. Nature469(7329):221–5.
